Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults

Journal of Infectious Diseases

Volumn 213, Issue 1, 2016, Pages 14-22

  Levin, Myron J ^a   Schmader, Kenneth E ^b   Pang, Lei ^c   Williams Diaz, Angela ^c   Zerbe, Gary ^a   Canniff, Jennifer ^a   Johnson, Michael J ^a   Caldas, Yupanqui ^a   Cho, Alice ^a   Lang, Nancy ^a   Su, Shu Chih ^c   Parrino, Janie ^c   Popmihajlov, Zoran ^c   Weinberg, Adriana ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b DUKE UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

herpes zoster vaccine; VZV antibodies; VZV cell mediated immunity (CMI)

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VARICELLA ZOSTER VIRUS ANTIBODY; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; TREATMENT RESPONSE; VACCINATION; VERY ELDERLY; BLOOD; CLINICAL TRIAL; FOLLOW UP; IMMUNOLOGY; SECONDARY IMMUNIZATION; VARICELLA ZOSTER VIRUS;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; FOLLOW-UP STUDIES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED;

EID: 84961999735     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv480     Document Type: Article

References (28)

1. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84
2. Schmader KE, Levin MJ, Gnaan JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54: 922-8
3. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197: 825-35
4. Levin MJ, Schmader KE, Gnann JW, et al. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis 2013; 208: 1386-90
5. Gilbert PB, Gabriel EE, Miao X, et al. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis 2014; 210: 1573-81
6. Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis 2010; 201: 1024-30
7. Levin MJ. Zoster vaccine. In: Plotkin S, OrensteinW, Offit P, eds. Vaccines. Atlanta, GA: Elsevier, 2013: 969-80
8. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010; 51: 197-213
9. Arvin AM, Sharp M, Moir M, et al. Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus. Viral Immunol 2002; 15: 507-16
10. Arvin AM, Sharp M, Smith S, et al. Equivalent recognition of a varicellazoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol 1991; 146: 257-64
11. Diaz PS, Smith S, Hunter E, Arvin AM. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 1989; 142: 636-41
12. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200: 1068-77
13. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-9
14. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004; 78: 5535-45
15. Akbar AN, Fletcher JM. Memory T cell homeostasis and senescence during aging. Curr Opin Immunol 2005; 17: 480-5
16. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007; 4: 9
17. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661-5
18. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366: 1165-74
19. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-60
20. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55: 1320-8
21. Morrison V, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60: 900-9
22. Hammond O, Wang Y, Green T, et al. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol 2006; 78: 1679-87
23. Weinberg A, Song LY, Wilkening CL, et al. Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. J Immunol Methods 2010; 363: 42-50
24. Tang H, Moriishi E, Okamoto S, et al. A community-based survey of varicellazoster virus-specific immune responses in the elderly. J Clin Virol 2012; 55: 46-50
25. Vermeulen JN, Lange JM, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine 2012; 30: 904-10
26. Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010; 152: 545-54
27. Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 2010; 28: 4204-9
28. Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis 2013; 208: 559-63